Could a cancer drug heal painful mouth sores in Behçet's?
NCT ID NCT05449548
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests the drug lenalidomide in 42 adults with Behçet's syndrome who have stubborn mouth ulcers. Participants take 10 mg of lenalidomide daily for 12 weeks, then stop for 4 weeks of observation. The main goal is to see if the ulcers completely disappear by week 12.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lenalidomide (a drug that modifies the immune system)
- What this could lead to
- If it works, this could offer a new treatment option for painful mouth ulcers in people with Behçet's syndrome that haven't responded to other therapies.
- What could go wrong
- This is a small, early-phase trial with no control group, so results may not be conclusive. Lenalidomide can have side effects like blood clots and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHÇET'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China